U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Tigecycline – Injection products
  1. Development Resources

Tigecycline – Injection products

FDA-Identified Interpretive Criteria

  Minimum Inhibitory
Concentrations
(mcg/mL)		 Disk Diffusion
(zone diameter in mm)
Pathogen S I R S I R
Staphylococcus aureus
(including methicillin-resistant
isolates)		 ≤0.5a - - ≥19 - -
Streptococcus spp. other than
S. pneumoniae		 ≤0.25a - - ≥19 - -
Streptococcus pneumoniae ≤0.06a - - ≥19 - -
Enterococcus faecalis
(vancomycin-susceptible
isolates)		 ≤0.25a - - ≥19 - -
Enterobacteralesb ≤2 4 ≥8 ≥19 15-18 ≤14
Haemophilus influenzae ≤0.25a - - ≥19 - -
Anaerobesc ≤4 8 ≥16 - - -

S = Susceptible; I = Intermediate; R = Resistant
For disk diffusion, use paper disks impregnated with 15 mcg tigecycline

a The current absence of resistant isolates precludes defining any results other than “Susceptible.” Isolates yielding MIC results suggestive of “Nonsusceptible” category should be submitted to reference laboratory for further testing.
b Tigecycline has decreased in vitro activity against Morganella spp., Proteus spp. and Providencia spp.
c Agar dilution

Back to Top